- Home
- NVR vs ILMN Comparison
NVR vs ILMN Comparison
Compare NVR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVR
- ILMN
- Stock Information
- Founded
- NVR 1980
- ILMN 1998
- Country
- NVR United States
- ILMN United States
- Employees
- NVR N/A
- ILMN N/A
- Industry
- NVR Homebuilding
- ILMN Medical Specialities
- Sector
- NVR Consumer Discretionary
- ILMN Health Care
- Exchange
- NVR Nasdaq
- ILMN Nasdaq
- Market Cap
- NVR 28.2B
- ILMN 23.6B
- IPO Year
- NVR N/A
- ILMN 2000
- Fundamental
- Price
- NVR $8,244.00
- ILMN $134.96
- Analyst Decision
- NVR Buy
- ILMN Buy
- Analyst Count
- NVR 4
- ILMN 17
- Target Price
- NVR $9,765.00
- ILMN $163.12
- AVG Volume (30 Days)
- NVR 22.5K
- ILMN 2.1M
- Earning Date
- NVR 01-28-2025
- ILMN 02-06-2025
- Dividend Yield
- NVR N/A
- ILMN N/A
- EPS Growth
- NVR 2.79
- ILMN N/A
- EPS
- NVR 488.66
- ILMN N/A
- Revenue
- NVR $10,281,399,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- NVR $6.32
- ILMN N/A
- Revenue Next Year
- NVR $5.91
- ILMN $4.05
- P/E Ratio
- NVR $16.87
- ILMN N/A
- Revenue Growth
- NVR 3.41
- ILMN N/A
- 52 Week Low
- NVR $6,800.00
- ILMN $97.36
- 52 Week High
- NVR $9,964.77
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- NVR 31.66
- ILMN 40.09
- Support Level
- NVR $7,986.00
- ILMN $130.31
- Resistance Level
- NVR $8,323.25
- ILMN $137.69
- Average True Range (ATR)
- NVR 193.48
- ILMN 5.13
- MACD
- NVR -44.19
- ILMN -1.03
- Stochastic Oscillator
- NVR 22.60
- ILMN 21.69
About NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the United States; Mid-Atlantic, North East, Mid-East, and South East.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.